Abstract
* The injected form of the antiemetic dolasetron mesylate (Anzemet) may increase a patient's risk of developing torsade de pointes when it's used to treat nausea and vomiting caused by chemotherapy.
* Patients with underlying heart conditions or other cardiac problems are at greatest risk.
* Patients can still use the injected form of the drug to prevent postoperative nausea because the dosage used is lower. Also, the oral form of the drug isn't thought to carry as high a risk of torsade de pointes.